{"content":"<li class=\"n-box-item date-title\" data-end=\"1482469199\" data-start=\"1482382800\" data-txt=\"Sunday, December 22, 2019\">Thursday, December 22, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3232331\" data-ts=\"1482457078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPRX\" target=\"_blank\">DPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232331-dipexium-to-merge-plx-pharma-in-all-stock-deal-shares-up-66-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dipexium to merge with PLx Pharma in all-stock deal; shares up 66% after hours</a></h4><ul>\n<li>Nano cap Dipexium Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/DPRX\" title=\"Dipexium Pharmaceuticals, LLC\">DPRX</a>) bolts <font color=\"green\">66%</font> after hours on increased volume in response to its announcement that has inked an agreement to merge with privately held <a href=\"http://plxpharma.com/\" target=\"_blank\">PLx Pharma</a> in an all-stock transaction. After the deal closes, expected in Q2 2017, the combined company will do business as PLx Pharma under the leadership of the PLx management. Dipexium chief Michael Valentino will serve as Executive Chairman.</li>\n<li>Under the terms of the merger, Dipexium will issue 36M new common shares to PLx stockholders who will own 76.75% of the new entity. Dipexium shareholders will own 23.25%.</li>\n<li>The combined company will initially focus on completing manufacturing scale-up and finalizing the label for conditionally approved <a href=\"http://plxpharma.com/products-tech/pl2200-aspirin/\" target=\"_blank\">Aspertec 325 mg</a> aspirin dose form and filing a supplemental New Drug Application for Aspertec 81 mg maintenance dose form.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232331\" data-linked=\"Dipexium to merge with PLx Pharma in all-stock deal; shares up 66% after hours\" data-tweet=\"$DPRX - Dipexium to merge with PLx Pharma in all-stock deal; shares up 66% after hours https://seekingalpha.com/news/3232331-dipexium-to-merge-plx-pharma-in-all-stock-deal-shares-up-66-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3232331-dipexium-to-merge-plx-pharma-in-all-stock-deal-shares-up-66-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232330\" data-ts=\"1482456138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232330-galena-reaches-settlement-former-ceo-in-sec-inquiry-over-dubious-stock-promotion-scheme\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena reaches settlement with former CEO in SEC inquiry over dubious stock promotion scheme; shares ahead 2% after hours</a></h4><ul>\n<li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/1390478/000139047816000167/gale-201612228xk.htm\" target=\"_blank\">regulatory filing</a>, Galena Biopharma (GALE) reports that it has agreed in principle to a settlement with former CEO Mark Ahn that should resolve a long-running investigation by the SEC into his alleged commissioning of an illicit internet-based scheme to inflate the stock price. The company fired Ahn in August 2014 over the controversy.</li>\n<li>Under the terms of the settlement, Galena will pay a $200K penalty and $750K as indemnification of the former CEO under Delaware law. Mr. Ahn will be personally responsible for paying his penalty of at least $600K.</li>\n<li>The SEC has yet to formally agree to the settlement.</li>\n<li>Shares are up <font color=\"green\">2%</font> after hours on light volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232330\" data-linked=\"Galena reaches settlement with former CEO in SEC inquiry over dubious stock promotion scheme; shares ahead 2% after hours\" data-tweet=\"$SLS - Galena reaches settlement with former CEO in SEC inquiry over dubious stock promotion scheme; shares ahead 2% after hours https://seekingalpha.com/news/3232330-galena-reaches-settlement-former-ceo-in-sec-inquiry-over-dubious-stock-promotion-scheme?source=tweet\" data-url=\"https://seekingalpha.com/news/3232330-galena-reaches-settlement-former-ceo-in-sec-inquiry-over-dubious-stock-promotion-scheme\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232329\" data-ts=\"1482454888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232329-synergy-pharmas-plecanatide-successful-in-second-late-stage-study-in-ibs-c-marketing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma&#39;s plecanatide successful in second late-stage study in IBS-C; marketing application on tap for Q1; shares ahead 11% after hours</a></h4><ul>\n<li>Synergy Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SGYP\" title=\"Synergy Pharmaceuticals, Inc.\">SGYP</a>) is up <font color=\"green\">11%</font> after hours on robust volume in response to its announcement of positive results in its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02493452?term=plecanatide&amp;cond=irritable+bowel+syndrome&amp;phase=2&amp;rank=2\" target=\"_blank\">second Phase 3</a> clinical trial assessing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C).</li>\n<li>The study met its primary endpoint of a statistically valid overall responder (OR) rate versus placebo at week 12. On a preliminary basis, the OR rates in the 3 mg and 6 mg plecanatide arms and placebo arm were 30.2%, 29.5% and 17.8%, respectively (p &lt;0.001 for both).</li>\n<li>The results echoed the positive results from the first Phase 3, announced two weeks ago.</li>\n<li>The company's New Drug Application (NDA) seeking approval for plecanatide to treat chronic ideopathic constipation is currently under FDA review with an action date of January 29. Assuming approval, it intends to file a supplemental NDA for IBS-C later in Q1.</li>\n<li>Plecanatide is the first investigational therapy designed to replicate the activity of <a href=\"https://en.wikipedia.org/wiki/Uroguanylin\" target=\"_blank\">uroguanylin</a>, a naturally occurring human gastrointestinal peptide, by working locally in the proximal small intestine to stimulate digestive fluid movement and support regular bowel function.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3229690-synergy-pharmas-plecanatide-successful-late-stage-ibs-c-study-shares-ahead-17-percent\" target=\"_blank\">Synergy Pharma's plecanatide successful in late-stage IBS-C study; shares ahead 17% premarket</a> (Dec. 9)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232329\" data-linked=\"Synergy Pharma&#39;s plecanatide successful in second late-stage study in IBS-C; marketing application on tap for Q1; shares ahead 11% after hours\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharma&#39;s plecanatide successful in second late-stage study in IBS-C; marketing application on tap for Q1; shares ahead 11% after hours https://seekingalpha.com/news/3232329-synergy-pharmas-plecanatide-successful-in-second-late-stage-study-in-ibs-c-marketing?source=tweet\" data-url=\"https://seekingalpha.com/news/3232329-synergy-pharmas-plecanatide-successful-in-second-late-stage-study-in-ibs-c-marketing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232328\" data-ts=\"1482448666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMT\" target=\"_blank\">LMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232328-lockheed-dips-boeing-rises-after-trump-tweets-on-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lockheed dips, Boeing rises after Trump tweets on costs</a></h4><ul>   <li>Lockheed Martin (NYSE:<a href=\"https://seekingalpha.com/symbol/LMT\" title=\"Lockheed Martin\">LMT</a>) slipped in after-hours trade, <font color=\"red\">down 2.1%</font>, after a tweet from President-elect Donald Trump dinging the company for costs.</li>    <li>\"Based on the tremendous cost and cost overruns of the Lockheed Martin F-35, I have asked Boeing to price-out a comparable F-18 Super Hornet!\" Trump <a href=\"https://twitter.com/realDonaldTrump/status/812061677160202240\" target=\"_blank\">tweeted</a> just a <a href=\"https://seekingalpha.com/news/3232235-lockheed-ceo-productive-meeting-trump\" target=\"_blank\">day after meeting</a> with the company's CEO.</li>    <li>Boeing (NYSE:<a href=\"https://seekingalpha.com/symbol/BA\" title=\"The Boeing Company\">BA</a>), for its part, is <font color=\"green\">up 0.8%</font> in the extended session after closing flat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232328\" data-linked=\"Lockheed dips, Boeing rises after Trump tweets on costs\" data-tweet=\"$LMT $LMT $BA - Lockheed dips, Boeing rises after Trump tweets on costs https://seekingalpha.com/news/3232328-lockheed-dips-boeing-rises-after-trump-tweets-on-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3232328-lockheed-dips-boeing-rises-after-trump-tweets-on-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232323\" data-ts=\"1482446213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232323-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li>\n<b>Top gainers, as of 5.25 p.m.:</b> <a href=\"https://seekingalpha.com/symbol/PGNX\" title=\"Progenics Pharmaceuticals Inc.\">PGNX</a> <font color=\"green\">+7.3%</font>. SGY <font color=\"green\">+4.5%</font>. <a href=\"https://seekingalpha.com/symbol/SGYP\" title=\"Synergy Pharmaceuticals, Inc.\">SGYP</a> <font color=\"green\">+3.4%</font>. <a href=\"https://seekingalpha.com/symbol/ZNGA\" title=\"Zynga\">ZNGA</a> <font color=\"green\">+2.7%</font>. <a href=\"https://seekingalpha.com/symbol/HBM\" title=\"Hudbay Minerals Inc Ordinary Sh\">HBM</a> <font color=\"green\">+2.2%</font>.</li>\n<li>\n<b>Top losers, as of 5.25p.m.:</b> <a href=\"https://seekingalpha.com/symbol/CASC\" title=\"Cascadian Therapeutics, Inc\">CASC</a> <font color=\"red\">-3.6%</font>. <a href=\"https://seekingalpha.com/symbol/STRL\" title=\"Sterling Construction Company Inc\">STRL</a> <font color=\"red\">-2.6%</font>. <a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a> <font color=\"red\">-1.7%</font>. <a href=\"https://seekingalpha.com/symbol/CZZ\" title=\"Cosan Limited\">CZZ</a> <font color=\"red\">-1.2%</font>. <a href=\"https://seekingalpha.com/symbol/CLF\" title=\"Cleveland-Cliffs, Inc.\">CLF</a> <font color=\"red\">-1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232323\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PGNX $TALO $SGYP-OLD - After Hours Gainers / Losers https://seekingalpha.com/news/3232323-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232323-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232316\" data-ts=\"1482443515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVHY\" target=\"_blank\">VIVHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232316-unyielding-vivendi-raises-stake-in-mediaset-to-28_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unyielding Vivendi raises stake in Mediaset to 28.8%</a></h4><ul>   <li>Pushing past objections from Ialian politicians, Vivendi (<a href=\"https://seekingalpha.com/symbol/VIVHY\" title=\"Vivendi SA ADR\">OTCPK:VIVHY</a> <font color=\"red\">-2%</font>) has raised its rapidly assembled stake in Mediaset (<a href=\"https://seekingalpha.com/symbol/MDIUY\" title=\"Mediaset S.p.A. ADR\">OTCPK:MDIUY</a> <font color=\"red\">-10.5%</font>) <a href=\"http://www.reuters.com/article/us-mediaset-vivendi-minister-idUSKBN14B1CQ?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202016-12-22&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">yet again -- to 28.8%</a>.</li>    <li>That puts it quite near the 30% threshold at which point it would need to make a full bid for the company.</li>    <li>Rhetoric between the two companies has ratcheted up throughout the year after a deal for Vivendi to buy Mediaset's pay TV arm, Mediaset Premium, fell through over the summer.</li>    <li>Meanwhile, Italian officials with a keen sense of nationally strategic companies have expressed unhappiness with the rapid approach of the French giant (which has made acquisitions in southern Europe part of its strategy) and its Chairman Vincent Bollore.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231976-vivendi-meet-italy-markets-regulator-mediaset\" target=\"_blank\">Vivendi to meet with Italy markets regulator over Mediaset</a> (Dec. 21 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232316\" data-linked=\"Unyielding Vivendi raises stake in Mediaset to 28.8%\" data-tweet=\"$VIVHY $VIVHY $MDIUY - Unyielding Vivendi raises stake in Mediaset to 28.8% https://seekingalpha.com/news/3232316-unyielding-vivendi-raises-stake-in-mediaset-to-28_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3232316-unyielding-vivendi-raises-stake-in-mediaset-to-28_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232315\" data-ts=\"1482442906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232315-progenicsplus-11-after-hours-trial-green-lighted-to-continue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progenics +11% after hours as trial green-lighted to continue</a></h4><ul>\n<li>Progenics' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PGNX\" title=\"Progenics Pharmaceuticals Inc.\">PGNX</a>) independent monitoring committee has completed its review of an interim analysis of the ongoing Phase 3 trial of the company's PSMA-targeted SPECT/CT imaging agent candidate, 99mTc-MIP-1404, and recommended it continue.</li>\n<li>Roughly 190 of a planned 450 patients have been enrolled to date.</li>\n<li>Shares <font color=\"green\">+11.2%</font> after hours.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232315\" data-linked=\"Progenics +11% after hours as trial green-lighted to continue\" data-tweet=\"$PGNX - Progenics +11% after hours as trial green-lighted to continue https://seekingalpha.com/news/3232315-progenicsplus-11-after-hours-trial-green-lighted-to-continue?source=tweet\" data-url=\"https://seekingalpha.com/news/3232315-progenicsplus-11-after-hours-trial-green-lighted-to-continue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232310\" data-ts=\"1482441627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPSH\" target=\"_blank\">CPSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232310-activist-sees-150-upside-in-cps-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist sees 150% upside in CPS Technologies</a></h4><ul>\n<li>In a letter to the board of CPS Technologies (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CPSH\" title=\"CPS Technologies Corp.\">CPSH</a>), Horton Capital Partners - an owner of about 4% of the stock - urges the company \"to be more proactive by making calculated investments in sales growth and cost reduction initiatives.\"</li>\n<li>Capital allocation needs to improve as well, says Horton, urging M&amp;A (buy or sell) and return of excess capital to owners.</li>\n<li><a href=\"http://thehortonfund.com/wp-content/uploads/2016/12/cpsbodletter121616Final.pdf\" target=\"_blank\">Full letter</a></li>\n<li>Shares <font color=\"green\">+3.6%</font> after hours.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232310\" data-linked=\"Activist sees 150% upside in CPS Technologies\" data-tweet=\"$CPSH - Activist sees 150% upside in CPS Technologies https://seekingalpha.com/news/3232310-activist-sees-150-upside-in-cps-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3232310-activist-sees-150-upside-in-cps-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232302\" data-ts=\"1482440770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALM\" target=\"_blank\">CALM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232302-cal-maine-foods-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cal-Maine Foods EPS in-line, misses on revenue</a></h4><ul>\n<li>Cal-Maine Foods (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CALM\" title=\"Cal-Maine Foods, Inc.\">CALM</a>): FQ2 EPS of -$0.48 in-line.</li>\n<li>Revenue of $253.55M (-53.6% Y/Y) <font color=\"red\">misses by $9.28M</font>.</li>\n<li>Shares <font color=\"green\">+1.9%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232302\" data-linked=\"Cal-Maine Foods EPS in-line, misses on revenue\" data-tweet=\"$CALM - Cal-Maine Foods EPS in-line, misses on revenue https://seekingalpha.com/news/3232302-cal-maine-foods-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3232302-cal-maine-foods-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232295\" data-ts=\"1482440238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232295-red-hat-downgraded-stifel-bmo-capital-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat downgraded at Stifel, BMO Capital Markets</a></h4><ul>\n<li>Coverage ratings are broadly maintained elsewhere subsequent Red Hat's <a href=\"https://seekingalpha.com/news/3232092-red-hat-minus-13_5-percent-q3-mixed-cfo-departs-guidance-light\" target=\"_blank\">Q3 reporting</a> [Baird \u2013 Outperform (lowers target to $85), Cowen and Company \u2013 Outperform (to $82), MKM Partners \u2013 Neutral (restates $75), Jefferies \u2013 Hold (to $76)] as Stifel and BMO Capital Markets come off respective Buy and Outperform grades.</li>\n<li>\n<a href=\"http://blogs.barrons.com/techtraderdaily/2016/12/22/red-hat-sinks-13-cfo-exit-q3-miss-raises-new-cloud-questions/\" target=\"_blank\">Analyst Brad Reback</a> (Stifel), while remaining optimistic Red Hat can sustain low double-digit growth on corporate data center positioning, highlights increasing concern certain products (OpenStack, OpenShift) are likely to stay niche offerings, and views restriction to upside as hyperscale cloud solutions from Amazon and Microsoft continue to grow rapidly as companies of all sizes adopt shifts to public clouds. Reduces target on Red Hat shares from $87 to $70.</li>\n<li>\n<a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8835390/weak-billings-growth-likely-to-dominate-the-red-hat-stor\" target=\"_blank\">Keith Bachman</a> (BMO Capital Markets), lowering target from $89 to $75, attributes concern over billings growth, continued deceleration and margins.</li>\n<li>Red Hat's (NYSE:<a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a>) closing out the session on <font color=\"red\">nearly 14% losses</font> to a $68.67 level.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232295\" data-linked=\"Red Hat downgraded at Stifel, BMO Capital Markets\" data-tweet=\"$RHT - Red Hat downgraded at Stifel, BMO Capital Markets https://seekingalpha.com/news/3232295-red-hat-downgraded-stifel-bmo-capital-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3232295-red-hat-downgraded-stifel-bmo-capital-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232292\" data-ts=\"1482438327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCS\" target=\"_blank\">BCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232292-barclaysminus-2-after-u-s-sues-over-mortgages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays -2% after U.S. sues over mortgages</a></h4><ul>\n<li>At issue are $31B in MBS sold by Barclays (<a href=\"https://seekingalpha.com/symbol/BCS\" title=\"Barclays PLC\">BCS</a> <font color=\"red\">-1.9%</font>) in the last bubble. According to the DOJ, <a href=\"https://www.bloomberg.com/news/articles/2016-12-22/u-s-sues-barclays-over-residential-mortgage-backed-securities-ix0rpe4f\" target=\"_blank\">more than half of the</a> underlying mortgages ended in default.</li>\n<li>It's not known how much the U.S. was seeking to settle, but it must have been plenty if Barclays prefers going to court.</li>\n<li>Barclays is among a small handful of lenders that haven't yet settled with the U.S., a group that most notably includes Deutsche Bank (<a href=\"https://seekingalpha.com/symbol/DB\" title=\"Deutsche Bank AG\">DB</a> <font color=\"red\">-0.9%</font>), but also Credit Suisse (<a href=\"https://seekingalpha.com/symbol/CS\" title=\"Credit Suisse Group AG\">CS</a> <font color=\"red\">-1.3%</font>) and Royal Bank of Scotland (<a href=\"https://seekingalpha.com/symbol/RBS\" title=\"The Royal Bank of Scotland Group plc\">RBS</a> <font color=\"red\">-0.7%</font>).</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232285-deal-u-s-sues-barclays-mortgages\" target=\"_blank\">No deal: U.S. sues Barclays over mortgages</a> (Dec. 22)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232292\" data-linked=\"Barclays -2% after U.S. sues over mortgages\" data-tweet=\"$BCS $BCS $DB - Barclays -2% after U.S. sues over mortgages https://seekingalpha.com/news/3232292-barclaysminus-2-after-u-s-sues-over-mortgages?source=tweet\" data-url=\"https://seekingalpha.com/news/3232292-barclaysminus-2-after-u-s-sues-over-mortgages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232291\" data-ts=\"1482437949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRKS\" target=\"_blank\">BRKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232291-brooks-automation-flies-to-nine-year-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brooks Automation flies to nine-year high</a></h4><ul>\n<li>Brooks Automation (<a href=\"https://seekingalpha.com/symbol/BRKS\" title=\"Brooks Automation, Inc.\">BRKS</a> <font color=\"green\">+4.2%</font>) spikes to a nine-year high after Janney Scott names the stock one of its top <a href=\"http://blogs.barrons.com/incomeinvesting/2016/12/21/the-life-sciences-stocks-with-the-perfect-dividend-growth-profiles/?mod=bol-social-tw\" target=\"_blank\">small cap picks</a>.</li>\n<li>Volume on BRKS today is already 2X normal activity.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232291\" data-linked=\"Brooks Automation flies to nine-year high\" data-tweet=\"$BRKS - Brooks Automation flies to nine-year high https://seekingalpha.com/news/3232291-brooks-automation-flies-to-nine-year-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3232291-brooks-automation-flies-to-nine-year-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232288\" data-ts=\"1482436809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232288-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/CPAH\" title=\"CounterPath Corporation\">CPAH</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/IPDN\" title=\"Professional Diversity Network\">IPDN</a> <font color=\"green\">+9%</font>. <a href=\"https://seekingalpha.com/symbol/QUIK\" title=\"QuickLogic Corporation\">QUIK</a> <font color=\"green\">+6%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a> <font color=\"red\">-13%</font>. DRAM <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/XGTI\" title=\"xG Technology, Inc.\">XGTI</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/NH\" title=\"NantHealth\">NH</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/HDP\" title=\"Hortonworks\">HDP</a> <font color=\"red\">-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232288\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$GSAT $MU $CPAH - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3232288-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232288-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232286\" data-ts=\"1482436119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232286-micron-technology-reissued-bullishly-targets-raised-credit-suisse-morgan-stanley-instinet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology reissued bullishly, targets raised at Credit Suisse, Morgan Stanley, Instinet</a></h4><ul>\n<li>Among similar sentiment <a href=\"https://seekingalpha.com/news/3232195-needham-and-company-issues-two-level-upgrade-buy-micron-technology\" target=\"_blank\">broadly issued</a> across Micron's coverage universe following communication of the company's positive <a href=\"https://seekingalpha.com/news/3232079-micron-technology-plus-7_4-percent-q1-estimates-outlook-robust\" target=\"_blank\">Q1 earnings</a>, outlook and <a href=\"https://seekingalpha.com/article/4032098-micron-technologys-mu-ceo-mark-durcan-q1-2017-results-earnings-call-transcript\" target=\"_blank\">management commentary</a>.</li>\n<li>\n<strong><a href=\"http://blogs.barrons.com/techtraderdaily/2016/12/22/micron-soars-13-partying-like-never-before-in-memory-chips-says-street/?mod=BOL_hp_blog_tt\" target=\"_blank\">Highlights</a></strong> \u2013 John Pitzer at Credit Suisse (to $30 target, adjusting from <a href=\"https://seekingalpha.com/news/3231128-micron-technology-plus-2_3-percent-early-target-raised-credit-suisse\" target=\"_blank\">updated target issued last week</a>) notes a DRAM pricing environment he considers sustainable through 2017, for NAND through at minimum H1 2017, and a cost gap that's closing with peers. Morgan Stanley's Joseph Moore (to $25) similarly expects strength in DRAM pricing to continue throughout the coming year, though considers NAND to be \"a bit more mixed.\" Romit Shah at Instinet (to $28) cites faster-than-anticipated improvement in margins and calculates Micron outgrowing the DRAM industry with a roughly 40% bit shipment rise in 2017.</li>\n<li>Micron (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a>) shares are at this point to $23.24, <font color=\"green\">+12.9%</font> on the day.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232286\" data-linked=\"Micron Technology reissued bullishly, targets raised at Credit Suisse, Morgan Stanley, Instinet\" data-tweet=\"$MU - Micron Technology reissued bullishly, targets raised at Credit Suisse, Morgan Stanley, Instinet https://seekingalpha.com/news/3232286-micron-technology-reissued-bullishly-targets-raised-credit-suisse-morgan-stanley-instinet?source=tweet\" data-url=\"https://seekingalpha.com/news/3232286-micron-technology-reissued-bullishly-targets-raised-credit-suisse-morgan-stanley-instinet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232285\" data-ts=\"1482435747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCS\" target=\"_blank\">BCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232285-no-deal-u-s-sues-barclays-over-mortgages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No deal: U.S. sues Barclays over mortgages</a></h4><ul><li>According to a Bloomberg report.</li><li><a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a> is slipping, now&nbsp;<font color='red'>down 1.5%&nbsp;</font>on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232285\" data-linked=\"No deal: U.S. sues Barclays over mortgages\" data-tweet=\"$BCS - No deal: U.S. sues Barclays over mortgages https://seekingalpha.com/news/3232285-no-deal-u-s-sues-barclays-over-mortgages?source=tweet\" data-url=\"https://seekingalpha.com/news/3232285-no-deal-u-s-sues-barclays-over-mortgages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232281\" data-ts=\"1482434447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAS\" target=\"_blank\">BAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232281-basic-energy-services-to-emerge-from-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Basic Energy Services to emerge from bankruptcy</a></h4><ul> <li>Basic Energy Services (NYSE:<a href=\"https://seekingalpha.com/symbol/BAS\" title=\"Basic Energy Services, Inc.\">BAS</a>) lands approval to list its new common stock on the NYSE under the symbol BAS after emerging from bankruptcy.</li> <li>The company estimates that it will come out of bankruptcy on December 23.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232281\" data-linked=\"Basic Energy Services to emerge from bankruptcy\" data-tweet=\"$BAS - Basic Energy Services to emerge from bankruptcy https://seekingalpha.com/news/3232281-basic-energy-services-to-emerge-from-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3232281-basic-energy-services-to-emerge-from-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232278\" data-ts=\"1482433204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232278-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> URRE <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+19%</font>. MPET <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TDW' title='Tidewater, Inc.'>TDW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CETC' title='Clean Enviro Tech Corp.'>CETC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-7%</font>. PGH <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232278\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$WWR $CHNR $TELL - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3232278-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232278-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232276\" data-ts=\"1482432085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232276-no-holiday-cheer-for-retail-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No holiday cheer for retail stocks</a></h4><ul>\n<li>The retail sector continues to get weak at its knees as concerns over the impact of trade and tax policies build up. Investors also have their eyes on a harsh take from MKM Partners on holiday traffic and NPD Group data suggesting the lack of any post-election bounce in retail sales.</li>\n<li>Boot Barn Holdings (<a href=\"https://seekingalpha.com/symbol/BOOT\" title=\"Boot Barn Holdings\">BOOT</a> <font color=\"red\">-7%</font>), Tailored Brands (<a href=\"https://seekingalpha.com/symbol/TLRD\" title=\"Tailored Brands, Inc\">TLRD</a> <font color=\"red\">-7.1%</font>), Ascena Retail Group (<a href=\"https://seekingalpha.com/symbol/ASNA\" title=\"Ascena Retail Group Inc\">ASNA</a> <font color=\"red\">-6%</font>), Zumiez (<a href=\"https://seekingalpha.com/symbol/ZUMZ\" title=\"Zumiez Inc.\">ZUMZ</a> <font color=\"red\">-6.1%</font>), Dick's Sporting Goods (<a href=\"https://seekingalpha.com/symbol/DKS\" title=\"Dick's Sporting Goods, Inc.\">DKS</a> <font color=\"red\">-6.5%</font>), Dillard's (<a href=\"https://seekingalpha.com/symbol/DDS\" title=\"Dillard's Inc.\">DDS</a> <font color=\"red\">-6.1%</font>), Zagg (<a href=\"https://seekingalpha.com/symbol/ZAGG\" title=\"ZAGG Inc\">ZAGG</a> <font color=\"red\">-6.3%</font>), Big Lots (<a href=\"https://seekingalpha.com/symbol/BIG\" title=\"Big Lots, Inc.\">BIG</a> <font color=\"red\">-5.5%</font>), Gap (<a href=\"https://seekingalpha.com/symbol/GPS\" title=\"The Gap, Inc.\">GPS</a> <font color=\"red\">-5.3%</font>), American Eagle Outfitters (<a href=\"https://seekingalpha.com/symbol/AEO\" title=\"American Eagle Outfitters, Inc.\">AEO</a> <font color=\"red\">-5.4%</font>), Guess (<a href=\"https://seekingalpha.com/symbol/GES\" title=\"Guess? Inc.\">GES</a> <font color=\"red\">-5.3%</font>) and Abercrombie &amp; Fitch (<a href=\"https://seekingalpha.com/symbol/ANF\" title=\"Abercrombie &amp; Fitch\">ANF</a> <font color=\"red\">-4.9%</font>) join the list of specialty retailers, C-store chains and heavyweight general merchandise names reported on earlier that are in descent.</li>\n<li>Sources: Bloomberg and CNBC</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232245-specialty-retailers-roughed-sales-growth-concerns\" target=\"_blank\">Specialty retailers roughed up on sales growth concerns</a> (Dec. 22)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232270-retail-stocks-clipped-concerns-taxes-trade\" target=\"_blank\">Retail stocks clipped on concerns over taxes and trade</a> (Dec. 22)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232276\" data-linked=\"No holiday cheer for retail stocks\" data-tweet=\"$BOOT $BOOT $TLRD - No holiday cheer for retail stocks https://seekingalpha.com/news/3232276-no-holiday-cheer-for-retail-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3232276-no-holiday-cheer-for-retail-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232272\" data-ts=\"1482430388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232272-wsj-blackstone-in-talks-for-5b-asset-buy-from-etp-shares-jump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Blackstone in talks for $5B asset buy from ETP; shares jump</a></h4><ul>   <li>Blackstone Group (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='red'>-1.3%</font>) is in talks to take a stake in assets of Energy Transfer Partners (ETP) that could <a href=\"http://www.wsj.com/articles/blackstone-in-talks-to-take-stake-in-energy-transfer-partners-assets-1482429832\" target=\"_blank\">top $5B in value</a>, <i>The Wall Street Journal</i> reports.</li>    <li>ETP is spiking in reaction, now <font color='green'>up 2.5%</font>.</li>    <li>The firm could join on a deal with Jamie Welch, who fell out with ETP honcho Kelcy Warren earlier this year.</li>    <li>The exact assets that would be involved in any deal weren't known.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232272\" data-linked=\"WSJ: Blackstone in talks for $5B asset buy from ETP; shares jump\" data-tweet=\"$ET $ET $BX - WSJ: Blackstone in talks for $5B asset buy from ETP; shares jump https://seekingalpha.com/news/3232272-wsj-blackstone-in-talks-for-5b-asset-buy-from-etp-shares-jump?source=tweet\" data-url=\"https://seekingalpha.com/news/3232272-wsj-blackstone-in-talks-for-5b-asset-buy-from-etp-shares-jump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232271\" data-ts=\"1482430204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCXI\" target=\"_blank\">CCXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232271-chemocentryx-out-licenses-lead-kidney-disease-candidate-ccx140-to-vifor-ex-u-s-and-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChemoCentryx out-licenses lead kidney disease candidate CCX140 to Vifor ex-U.S. and China; shares up 6%</a></h4><ul>\n<li>ChemoCentryx (<a href=\"https://seekingalpha.com/symbol/CCXI\" title=\"ChemoCentryx\">CCXI</a> <font color=\"green\">+5.6%</font>) inks a license and collaboration <a href=\"https://www.sec.gov/Archives/edgar/data/1340652/000119312516801528/d275906d8k.htm\" target=\"_blank\">agreement </a>with Galencia Group's <a href=\"http://www.viforpharma.com/en/About-Vifor/about-home.php\" target=\"_blank\">Vifor Pharma</a> granting the latter exclusive commercialization rights (except the U.S. and China) to CCR2 inhibitor <a href=\"http://www.chemocentryx.com/pipeline/chronic-kidney-disease/\" target=\"_blank\">CCX140</a>, in development for the treatment of diabetic nephropathy.  Vifor also has non-exclusive manufacturing rights and an exclusive option to develop CCX140 for chronic kidney disease (CKD) in its territory and the U.S. If the FDA approves the product for CKD, ChemoCentryx has the right to co-promote in the U.S.</li>\n<li>Both companies will equally share costs and expenses related to the development of CCX140, subject to a cap on ChemoCentryx's obligation. Vifor will foot the entire bill for the CKD indication.</li>\n<li>Under the terms of the agreement, Vifor will pay ChemCentryx $50M in two installments, milestones and royalties on commercial sales.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232271\" data-linked=\"ChemoCentryx out-licenses lead kidney disease candidate CCX140 to Vifor ex-U.S. and China; shares up 6%\" data-tweet=\"$CCXI - ChemoCentryx out-licenses lead kidney disease candidate CCX140 to Vifor ex-U.S. and China; shares up 6% https://seekingalpha.com/news/3232271-chemocentryx-out-licenses-lead-kidney-disease-candidate-ccx140-to-vifor-ex-u-s-and-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3232271-chemocentryx-out-licenses-lead-kidney-disease-candidate-ccx140-to-vifor-ex-u-s-and-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232270\" data-ts=\"1482429789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASY\" target=\"_blank\">CASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232270-retail-stocks-clipped-on-concerns-over-taxes-and-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail stocks clipped on concerns over taxes and trade</a></h4><ul>\n<li>Retail stocks are lower on a mix of news that includes the sharp drop in durable goods orders, soft earnings reports (<a href=\"https://seekingalpha.com/symbol-jq/BBBY/news\" target=\"_blank\">Bed Bath &amp; Beyond</a>), cautious analyst notes and perhaps the biggest drag of all - talk of an import tax.</li>\n<li>A new Trump wildcard also emerged when Carl Icahn was named as a special advisor to the new administration. Icahn is a critic of the trading of biofuel Renewable Identification Numbers (known as RINs). Retail chains that sell gas sometimes benefit from the RIN program.</li>\n<li>Casey's General Stores (<a href=\"https://seekingalpha.com/symbol/CASY\" title=\"Casey's General Stores, Inc.\">CASY</a> <font color=\"red\">-2%</font>), Alimentation Touche Card (<a href=\"https://seekingalpha.com/symbol/ANCUF\" title=\"Alimentation Couche-Tard Inc.\">OTCPK:ANCUF</a> <font color=\"red\">-1.5%</font>), Murphy USA (<a href=\"https://seekingalpha.com/symbol/MUSA\" title=\"Murphy USA, Inc.\">MUSA</a> <font color=\"red\">-4.6%</font>), Kroger (<a href=\"https://seekingalpha.com/symbol/KR\" title=\"Kroger Co.\">KR</a> <font color=\"red\">-0.5%</font>), Sprouts Farmers Market (<a href=\"https://seekingalpha.com/symbol/SFM\" title=\"Sprouts Farmers Market\">SFM</a> <font color=\"red\">-3.3%</font>), Supervalu (<a href=\"https://seekingalpha.com/symbol/SVU\" title=\"SUPERVALU Inc.\">SVU</a> <font color=\"red\">-3.5%</font>), Ingles Markets (<a href=\"https://seekingalpha.com/symbol/IMKTA\" title=\"Ingles Markets, Incorporated\">IMKTA</a> <font color=\"red\">-2.9%</font>) and Weis Markets (<a href=\"https://seekingalpha.com/symbol/WMK\" title=\"Weis Markets Inc\">WMK</a> <font color=\"red\">-1.5%</font>) are all notably lower off the mix of news.</li>\n<li>Wal-Mart (<a href=\"https://seekingalpha.com/symbol/WMT\" title=\"Walmart Inc.\">WMT</a> <font color=\"red\">-2.2%</font>), Target (<a href=\"https://seekingalpha.com/symbol/TGT\" title=\"Target Corporation\">TGT</a> <font color=\"red\">-3.4%</font>) and Dollar General (<a href=\"https://seekingalpha.com/symbol/DG\" title=\"Dollar General Corporation\">DG</a> <font color=\"red\">-3.7%</font>) are also trading off.</li>\n<li>Earlier: <a href=\"https://seekingalpha.com/news/3232245-specialty-retailers-roughed-sales-growth-concerns\" target=\"_blank\">Specialty retailers roughed up on sales growth concerns</a>\n</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/XLY\" title=\"Consumer Discretionary Select Sector SPDR ETF\">XLY</a>, <a href=\"https://seekingalpha.com/symbol/XRT\" title=\"SPDR S&amp;P Retail ETF\">XRT</a>, <a href=\"https://seekingalpha.com/symbol/VCR\" title=\"Vanguard Consumer Discretionary ETF\">VCR</a>, <a href=\"https://seekingalpha.com/symbol/RTH\" title=\"VanEck Vectors Retail ETF\">RTH</a>, <a href=\"https://seekingalpha.com/symbol/RETL\" title=\"Direxion Daily Retail Bull 3x Shares ETF\">RETL</a>, <a href=\"https://seekingalpha.com/symbol/IYK\" title=\"iShares U.S. Consumer Goods ETF\">IYK</a>, <a href=\"https://seekingalpha.com/symbol/FXD\" title=\"First Trust Consumer Discretionary AlphaDEX ETF\">FXD</a>, <a href=\"https://seekingalpha.com/symbol/IYC\" title=\"iShares U.S. Consumer Services ETF\">IYC</a>, <a href=\"https://seekingalpha.com/symbol/FDIS\" title=\"Fidelity MSCI Consumer Discretionary Index ETF\">FDIS</a>, <a href=\"https://seekingalpha.com/symbol/SCC\" title=\"ProShares UltraShort Consumer Services ETF\">SCC</a>, <a href=\"https://seekingalpha.com/symbol/RCD\" title=\"Invesco S&amp;P Equal Weight Consumer Discretionary ETF\">RCD</a>, <a href=\"https://seekingalpha.com/symbol/UCC\" title=\"ProShares Ultra Consumer Services ETF\">UCC</a>, <a href=\"https://seekingalpha.com/symbol/PMR\" title=\"Invesco Dynamic Retail Portfolio ETF\">PMR</a>, <a href=\"https://seekingalpha.com/symbol/UGE\" title=\"ProShares Ultra Consumer Goods ETF\">UGE</a>, <a href=\"https://seekingalpha.com/symbol/SZK\" title=\"ProShares UltraShort Consumer Goods ETF\">SZK</a>, <a href=\"https://seekingalpha.com/symbol/CNDF\" title=\"iShares Edge MSCI Multifactor Consumer Discretionary ETF\">CNDF</a>, <a href=\"https://seekingalpha.com/symbol/FTXD\" title=\"First Trust Nasdaq Retail ETF\">FTXD</a>, <a href=\"https://seekingalpha.com/symbol/JHMC\" title=\"John Hancock Multifactor Consumer Discretionary ETF\">JHMC</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232270\" data-linked=\"Retail stocks clipped on concerns over taxes and trade\" data-tweet=\"$CASY $CASY $ANCUF - Retail stocks clipped on concerns over taxes and trade https://seekingalpha.com/news/3232270-retail-stocks-clipped-on-concerns-over-taxes-and-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3232270-retail-stocks-clipped-on-concerns-over-taxes-and-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232268\" data-ts=\"1482429643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232268-canaccord-genuity-retains-calamp-buy-amid-6-post-earnings-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord Genuity retains CalAmp at Buy amid 6%+ post-earnings fall</a></h4><ul>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Cuts+Price+Target+on+Calamp+Corp.+%28CAMP%29+to+%2423+Following+3Q+Report/12366812.html\" target=\"_blank\">Analyst Michael Walkley</a>, decreasing target from $25 to $23, continues to view CalAmp favorably on improving North American MRM market trends, Q4 and FY 2017 guidance posted above firm's expectations, long-term growth opportunities stemming from LoJack acquisition, ramping worldwide sales, an expanding product portfolio, a growing list of new customer wins and other catalysts.</li>\n<li>Shares (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CAMP\" title=\"CalAmp Corp.\">CAMP</a>) to $14.74 on the session.</li>\n<li>Q3 earnings / <a href=\"https://seekingalpha.com/article/4032092-calamps-camp-ceo-michael-burdiek-q3-2017-results-earnings-call-transcript\" target=\"_blank\">call transcript</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232268\" data-linked=\"Canaccord Genuity retains CalAmp at Buy amid 6%+ post-earnings fall\" data-tweet=\"$CAMP - Canaccord Genuity retains CalAmp at Buy amid 6%+ post-earnings fall https://seekingalpha.com/news/3232268-canaccord-genuity-retains-calamp-buy-amid-6-post-earnings-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/3232268-canaccord-genuity-retains-calamp-buy-amid-6-post-earnings-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232269\" data-ts=\"1482429626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232269-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Losers:</b> WAC <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DMLP' title='Dorchester Minerals, L.P.'>DMLP</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232269\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$DHCP $DMLP - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3232269-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232269-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232261\" data-ts=\"1482428723\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232261-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Gainers:</b> TKAI <font color=\"green\">+37%</font>. <a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a> <font color=\"green\">+28%</font>. <a href=\"https://seekingalpha.com/symbol/CHNR\" title=\"China Natural Resources, Inc.\">CHNR</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/NM\" title=\"Navios Maritime Holdings Inc.\">NM</a> <font color=\"green\">+21%</font>. URRE <font color=\"green\">+17%</font>. <a href=\"https://seekingalpha.com/symbol/CETX\" title=\"Cemtrex, Inc.\">CETX</a> <font color=\"green\">+17%</font>. <a href=\"https://seekingalpha.com/symbol/ALBO\" title=\"Albireo Pharma, Inc.\">ALBO</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/IMMY-OLD\" title=\"Imprimis Pharmaceuticals, Inc.\">IMMY-OLD</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/CVRR\" title=\"CVR Refining, LP\">CVRR</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/EYES\" title=\"Second Sight Medical Products\">EYES</a> <font color=\"green\">+13%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/OVAS-OLD\" title=\"OvaScience, Inc.\">OVAS-OLD</a> <font color=\"red\">-52%</font>. <a href=\"https://seekingalpha.com/symbol/AUPH\" title=\"Aurinia Pharmaceuticals Inc.\">AUPH</a> <font color=\"red\">-21%</font>. LPTN <font color=\"red\">-18%</font>. <a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/BEBE\" title=\"bebe stores, inc.\">OTC:BEBE</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/AIR\" title=\"AAR Corporation\">AIR</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/GLBS\" title=\"Globus Maritime Ltd.\">GLBS</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/BBBY\" title=\"Bed Bath &amp; Beyond Inc.\">BBBY</a> <font color=\"red\">-9%</font>. WAC <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/ASMB\" title=\"Assembly Biosciences, Inc.\">ASMB</a> <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232261\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$NVUS $GSAT $CHNR - Midday Gainers / Losers https://seekingalpha.com/news/3232261-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232261-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232257\" data-ts=\"1482426874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRTN\" target=\"_blank\">TRTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232257-tritonminus-5-caiminus-3-on-trade-slowdown-worry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Triton -5%, CAI -3% on trade slowdown worry</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3232177-china-mulls-trumps-trade-pick\" target=\"_blank\">The selection of </a>China trade hawk Peter Navarro to head trade policy inside the White House, not to mention chatter about a 5% U.S. import tariff may have a trade slowdown on the minds of investors in Triton International (<a href='https://seekingalpha.com/symbol/TRTN' title='Triton International Limited'>TRTN</a> <font color='red'>-5.1%</font>) and CAI International (<a href='https://seekingalpha.com/symbol/CAI' title='CAI International, Inc.'>CAI</a> <font color='red'>-3.4%</font>), among others.</li><li>Of the 5% tariff, Trump spokesman Jason Miller says it's too soon to speculate on the details of trade policy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232257\" data-linked=\"Triton -5%, CAI -3% on trade slowdown worry\" data-tweet=\"$TRTN $TRTN $CAI - Triton -5%, CAI -3% on trade slowdown worry https://seekingalpha.com/news/3232257-tritonminus-5-caiminus-3-on-trade-slowdown-worry?source=tweet\" data-url=\"https://seekingalpha.com/news/3232257-tritonminus-5-caiminus-3-on-trade-slowdown-worry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232256\" data-ts=\"1482426556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232256-u-s-regulatory-ok-of-abbott-st-jude-marriage-imminent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. regulatory OK of Abbott/St. Jude marriage imminent</a></h4><ul>\n<li>Reuters <a href=\"http://www.reuters.com/article/us-stjude-m-a-abbott-idUSKBN14B1XW\" target=\"_blank\">reports</a> that the U.S. Federal Trade Commission is about to approve Abbott's (<a href=\"https://seekingalpha.com/symbol/ABT\" title=\"Abbott Laboratories\">ABT</a> <font color=\"green\">+0.1%</font>) intended takeover of St. Jude Medical (<a href=\"https://seekingalpha.com/symbol/STJ\" title=\"St. Jude Medical, Inc.\">STJ</a> <font color=\"green\">+0.5%</font>).</li>\n<li>European regulators blessed the deal in November with the proviso that the two firms divest two devices used in cardiovascular treatments. It is unknown whether the FTC will impose similar conditions.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232256\" data-linked=\"U.S. regulatory OK of Abbott/St. Jude marriage imminent\" data-tweet=\"$ABT $ABT $STJ - U.S. regulatory OK of Abbott/St. Jude marriage imminent https://seekingalpha.com/news/3232256-u-s-regulatory-ok-of-abbott-st-jude-marriage-imminent?source=tweet\" data-url=\"https://seekingalpha.com/news/3232256-u-s-regulatory-ok-of-abbott-st-jude-marriage-imminent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232254\" data-ts=\"1482426018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232254-consumers-top-5-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumers - Top 5 Gainers / Losers as of 12:00 PM</a></h4><ul>\n<li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/WATT\" title=\"Energous Corp.\">WATT</a> <font color=\"green\">+10%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/WGO\" title=\"Winnebago Industries, Inc.\">WGO</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/AVP\" title=\"Avon Products, Inc.\">AVP</a> <font color=\"red\">-5%</font>. XNY <font color=\"red\">-5%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232254\" data-linked=\"Consumers - Top 5 Gainers / Losers as of 12:00 PM\" data-tweet=\"$WATT $WGO $AVP - Consumers - Top 5 Gainers / Losers as of 12:00 PM https://seekingalpha.com/news/3232254-consumers-top-5-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232254-consumers-top-5-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232245\" data-ts=\"1482424021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232245-specialty-retailers-roughed-up-on-sales-growth-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Specialty retailers roughed up on sales growth concerns</a></h4><ul> <li>An unexpected drop in comparable sales at Bed Bath &amp; Beyond (<a href=\"https://seekingalpha.com/symbol/BBBY\" title=\"Bed Bath &amp; Beyond Inc.\">BBBY</a> <font color=\"red\">-7.1%</font>) during Q3 isn't going unnoticed in the specialty retail sector. A B. Riley <a href=\"https://seekingalpha.com/news/3232162-b-riley-neutral-kirklands-sizzling-run\" target=\"_blank\">downgrade</a> on Kirkland's (<a href=\"https://seekingalpha.com/symbol/KIRK\" title=\"Kirkland's, Inc.\">KIRK</a> <font color=\"red\">-8%</font>) could also be factoring in.</li> <li>Chains that sell household items and accessories are being the hardest hit off of the BBBY numbers and KIRK ratings cut.</li> <li>Decliners include Restoration Hardware (<a href=\"https://seekingalpha.com/symbol/RH\" title=\"RH\">RH</a> <font color=\"red\">-3.3%</font>), Pier 1 Imports (<a href=\"https://seekingalpha.com/symbol/PIR\" title=\"Pier 1 Imports Inc.\">PIR</a> <font color=\"red\">-4.4%</font>), Ethan Allen (<a href=\"https://seekingalpha.com/symbol/ETH\" title=\"Ethan Allen Interiors Inc.\">ETH</a> <font color=\"red\">-1.6%</font>) The Container Store (<a href=\"https://seekingalpha.com/symbol/TCS\" title=\"The Container Store Group, Inc.\">TCS</a> <font color=\"red\">-7.6%</font>), Party City (<a href=\"https://seekingalpha.com/symbol/PRTY\" title=\"Party City Holdco, Inc.\">PRTY</a> <font color=\"red\">-4.4%</font>), The Michaels Company (<a href=\"https://seekingalpha.com/symbol/MIK\" title=\"The Michaels Companies\">MIK</a> <font color=\"red\">-2.7%</font>), and Williams Sonoma (<a href=\"https://seekingalpha.com/symbol/WSM\" title=\"Williams-Sonoma Inc.\">WSM</a> <font color=\"red\">-5.1%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232245\" data-linked=\"Specialty retailers roughed up on sales growth concerns\" data-tweet=\"$BBBY $BBBY $KIRK - Specialty retailers roughed up on sales growth concerns https://seekingalpha.com/news/3232245-specialty-retailers-roughed-up-on-sales-growth-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3232245-specialty-retailers-roughed-up-on-sales-growth-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232244\" data-ts=\"1482423803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRM\" target=\"_blank\">NDRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232244-neuroderm-advances-mid-stage-study-of-nd0612h-in-parkinsons-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroDerm advances mid-stage study of ND0612H in Parkinson&#39;s; shares ahead 4%</a></h4><ul>\n<li>NeuroDerm (<a href=\"https://seekingalpha.com/symbol/NDRM\" title=\"NeuroDerm\">NDRM</a> <font color=\"green\">+4.3%</font>) announces the completion of enrollment and treatment in its 38-subject Phase 2 clinical trial (trial 006) assessing ND0612H in patients suffering from advanced Parkinson's disease (PD).</li>\n<li>The study is evaluating two dosing regimens of the high dose version of ND0612 compared with baseline oral standard of care. Top-line results should be available in Q1.</li>\n<li>ND0612H is designed to deliver steady subcutaneous doses of levodopa/carbidopa via a belt pump to PD patients with inadequately controlled motor fluctuations.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232244\" data-linked=\"NeuroDerm advances mid-stage study of ND0612H in Parkinson&#39;s; shares ahead 4%\" data-tweet=\"$NDRM - NeuroDerm advances mid-stage study of ND0612H in Parkinson&#39;s; shares ahead 4% https://seekingalpha.com/news/3232244-neuroderm-advances-mid-stage-study-of-nd0612h-in-parkinsons-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3232244-neuroderm-advances-mid-stage-study-of-nd0612h-in-parkinsons-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232239\" data-ts=\"1482422766\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232239-enrollment-completed-in-protalix-bios-mid-stage-study-of-air-dnase-in-cystic-fibrosis-top\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enrollment completed in Protalix Bio&#39;s mid-stage study of AIR DNase in cystic fibrosis, top-line data expected in two weeks; shares up 5%</a></h4><ul>\n<li>Protalix BioTherapeutics (<a href=\"https://seekingalpha.com/symbol/PLX\" title=\"Protalix BioTherapeutics, Inc\">PLX</a> <font color=\"green\">+4.9%</font>) says the last patient has been enrolled in its Phase 2 study assessing AIR DNase (PRX-110) in cystic fibrosis (CF). Top-data should be available in the first week of January with complete results to follow by the end of Q1.</li>\n<li>According to the company, <a href=\"http://www.protalix.com/development-pipeline/prx-110-dnase.asp\" target=\"_blank\">AIR DNase</a> is a proprietary plant cell-expressed recombinant form of a human enzyme called deoxyribonuclease 1 (DNase 1) that cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of CF sufferers. It is designed to be more effective than Roche's (<a href=\"https://seekingalpha.com/symbol/RHHBY\" title=\"Roche Holding Ltd ADR\">OTCQX:RHHBY</a>) <a href=\"http://www.pulmozyme.com/\" target=\"_blank\">Pulmozyme</a> (dornase alfa) by being more resistant to actin inhibition, which restricts DNase I activity. <a href=\"https://en.wikipedia.org/wiki/Actin\" target=\"_blank\">Actin</a> is a protein that plays a role in a wide range of cellular processes.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3192155-protalixs-mid-stage-study-air-dnase-cystic-fibrosis-underway\" target=\"_blank\">Protalix's mid-stage study of AIR DNase in cystic fibrosis underway</a> (July 7)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232239\" data-linked=\"Enrollment completed in Protalix Bio&#39;s mid-stage study of AIR DNase in cystic fibrosis, top-line data expected in two weeks; shares up 5%\" data-tweet=\"$PLX $PLX $RHHBY - Enrollment completed in Protalix Bio&#39;s mid-stage study of AIR DNase in cystic fibrosis, top-line data expected in two weeks; shares up 5% https://seekingalpha.com/news/3232239-enrollment-completed-in-protalix-bios-mid-stage-study-of-air-dnase-in-cystic-fibrosis-top?source=tweet\" data-url=\"https://seekingalpha.com/news/3232239-enrollment-completed-in-protalix-bios-mid-stage-study-of-air-dnase-in-cystic-fibrosis-top\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232213\" data-ts=\"1482422718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232213-healthcare-top-5-gainers-losers-of-11-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:05 am</a></h4><ul>\n<li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/ALBO\" title=\"Albireo Pharma, Inc.\">ALBO</a> <font color=\"green\">+14%</font>. TKAI <font color=\"green\">+48%</font>. <a href=\"https://seekingalpha.com/symbol/IMMY-OLD\" title=\"Imprimis Pharmaceuticals, Inc.\">IMMY-OLD</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/EYES\" title=\"Second Sight Medical Products\">EYES</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/CATB\" title=\"Catabasis Pharmaceuticals\">CATB</a> <font color=\"green\">+9%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/OVAS-OLD\" title=\"OvaScience, Inc.\">OVAS-OLD</a> <font color=\"red\">-51%</font>. <a href=\"https://seekingalpha.com/symbol/AUPH\" title=\"Aurinia Pharmaceuticals Inc.\">AUPH</a> <font color=\"red\">-22%</font>. LPTN <font color=\"red\">-19%</font>. <a href=\"https://seekingalpha.com/symbol/DCTH\" title=\"Delcath Systems, Inc.\">OTC:DCTH</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/AVGR\" title=\"Avinger\">AVGR</a> <font color=\"red\">-7%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232213\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:05 am\" data-tweet=\"$ALBO $NVUS $IMMY-OLD - Healthcare - Top 5 Gainers / Losers as of 11:05 am https://seekingalpha.com/news/3232213-healthcare-top-5-gainers-losers-of-11-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3232213-healthcare-top-5-gainers-losers-of-11-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232237\" data-ts=\"1482422074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEO\" target=\"_blank\">NEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232237-neogenomics-secures-new-150m-credit-facility-lower-guidance-sinks-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeoGenomics secures new $150M credit facility; lower guidance sinks shares, down 4%</a></h4><ul>\n<li>Thinly traded micro cap NeoGenomics (<a href=\"https://seekingalpha.com/symbol/NEO\" title=\"NeoGenomics Inc.\">NEO</a> <font color=\"red\">-3.7%</font>) eases on light volume in response to its downward revision to its 2016 guidance brought about by delays in recognizing ~$2M in Pharma Services revenue this quarter.</li>\n<li>The company now expects non-GAAP net income of $12M - 14M (from $13M - 15M) on revenues of $244M - 246M (from $245M - 250M). Non-GAAP EPS should be $0.13 - 0.15 (from $0.14 - 0.16).</li>\n<li>The company has closed a new five-year $150M senior secured credit facility that includes a $75M revolver and $75M term loan. It immediately borrowed $97.9M to retire its existing $54.6M term loan, redeem 8,066,667 shares of Series A Redeemable Preferred Stock held by an affiliate of General Electric for $55M and pay fees and expenses (along with $16M of cash on hand).</li>\n<li>The interest rate is LIBOR + 3%, a better deal that the prior rate of LIBOR + 7%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232237\" data-linked=\"NeoGenomics secures new $150M credit facility; lower guidance sinks shares, down 4%\" data-tweet=\"$NEO - NeoGenomics secures new $150M credit facility; lower guidance sinks shares, down 4% https://seekingalpha.com/news/3232237-neogenomics-secures-new-150m-credit-facility-lower-guidance-sinks-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3232237-neogenomics-secures-new-150m-credit-facility-lower-guidance-sinks-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232233\" data-ts=\"1482421290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRM\" target=\"_blank\">NDRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232233-neuroderm-grosses-over-86m-in-equity-offering-after-underwriters-step-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroDerm grosses over $86M in equity offering after underwriters step up</a></h4><ul>\n<li>NeuroDerm (<a href=\"https://seekingalpha.com/symbol/NDRM\" title=\"NeuroDerm\">NDRM</a> <font color=\"green\">+2.8%</font>) announces the full exercise of 600K additional shares by underwriters in its 4M-shares public offering at $18.75. Total gross proceeds were $86.25M.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3230004-neuroderm-closes-75m-follow-equity-offering\" target=\"_blank\">NeuroDerm closes $75M follow-on equity offering</a> (Dec. 12)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232233\" data-linked=\"NeuroDerm grosses over $86M in equity offering after underwriters step up\" data-tweet=\"$NDRM - NeuroDerm grosses over $86M in equity offering after underwriters step up https://seekingalpha.com/news/3232233-neuroderm-grosses-over-86m-in-equity-offering-after-underwriters-step-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3232233-neuroderm-grosses-over-86m-in-equity-offering-after-underwriters-step-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232222\" data-ts=\"1482421278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANY\" target=\"_blank\">ANY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232222-sphere-3d-stakeholder-presses-for-restructure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sphere 3D stakeholder presses for restructure</a></h4><ul>\n<li>Cyrus Capital Partners, holder of 28.3% equity interest (also holds debt through several loan instruments) in Sphere 3D, <a href=\"https://seekingalpha.com/filing/3332757\" target=\"_blank\">issued letter</a> on December 20 outlining management, operational and performance concerns held by the firm, which furthermore resigns a partner from the Sphere 3D board.</li>\n<li>Citing frustration, lays out areas of address including separation of Sphere 3D assets into distinct operational segments, establishment of wholly-owned subsidiaries to maintain assets associated with each segment, certain debt-for-equity exchange, management and compensation modifications, and consideration of options to improve revenue growth across Sphere 3D's businesses.</li>\n<li>In response, Sphere 3D \"views the letter to be indicative of Cyrus\u2019s belief that the business has yet to reach its full potential, and there is an opportunity to maximize shareholder value.\"</li>\n<li>Sphere 3D (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ANY\" title=\"Sphere 3D Corp.\">ANY</a>) shares <font color=\"red\">-7.50%</font>.</li>\n<li>Earlier this week (December 19): <a href=\"https://seekingalpha.com/news/3231451-sphere-3d-receives-second-unsolicited-expression-interest\" target=\"_blank\">Sphere 3D receives second, unsolicited expression of interest</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232222\" data-linked=\"Sphere 3D stakeholder presses for restructure\" data-tweet=\"$ANY - Sphere 3D stakeholder presses for restructure https://seekingalpha.com/news/3232222-sphere-3d-stakeholder-presses-for-restructure?source=tweet\" data-url=\"https://seekingalpha.com/news/3232222-sphere-3d-stakeholder-presses-for-restructure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232232\" data-ts=\"1482421202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232232-natural-gas-inventory-declines-sharply\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory declines sharply</a></h4><ul>\n<li>\n<a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>-209</strong><strong> Bcf</strong> vs. -201 Bcf consensus -147 Bcf last week.</li>\n<li>Futures <font color=\"green\">+0.7%</font> to $3.567.</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/UNG\" title=\"The United States Natural Gas ETF, LP\">UNG</a>, <a href=\"https://seekingalpha.com/symbol/DGAZ\" title=\"VelocityShares 3x Inverse Natural Gas ETN\">DGAZ</a>, <a href=\"https://seekingalpha.com/symbol/UGAZ\" title=\"VelocityShares 3x Long Natural Gas ETN\">UGAZ</a>, <a href=\"https://seekingalpha.com/symbol/BOIL\" title=\"ProShares Ultra Bloomberg Natural Gas ETF\">BOIL</a>, <a href=\"https://seekingalpha.com/symbol/GAZ\" title=\"iPath DJ-UBS Natural Gas Total Return Sub-Index ETN\">GAZ</a>, <a href=\"https://seekingalpha.com/symbol/KOLD\" title=\"ProShares UltraShort Bloomberg Natural Gas ETF\">KOLD</a>, <a href=\"https://seekingalpha.com/symbol/UNL\" title=\"The United States 12 Month Natural Gas ETF, LP\">UNL</a>, <a href=\"https://seekingalpha.com/symbol/DCNG\" title=\"iPath Pure Beta Seasonal Natural Gas ETN\">DCNG</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232232\" data-linked=\"Natural gas inventory declines sharply\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory declines sharply https://seekingalpha.com/news/3232232-natural-gas-inventory-declines-sharply?source=tweet\" data-url=\"https://seekingalpha.com/news/3232232-natural-gas-inventory-declines-sharply\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232230\" data-ts=\"1482420939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232230-finish-line-sliced-and-diced-analysts-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line sliced and diced by analysts after earnings</a></h4><ul> <li>Analyst revisions are raining down on Finish Line (<a href=\"https://seekingalpha.com/symbol/FINL\" title=\"The Finish Line, Inc.\">FINL</a> <font color=\"red\">-4%</font>) after the retailer's Q3 report and guidance is picked apart.</li> <li>\n<a href=\"https://www.marketbeat.com/stocks/NASDAQ/FINL/\" target=\"_blank\">Cuts</a>: BAML to Neutral from Buy, Monness Crespi to Neutral from Buy, Wedbush to Neutral with a $20 PT, Canaccord to Hold with a $22 PT, B. Riley to Neutral with a $22 PT.</li> <li>Wedbush analyst Christopher Svezia <a href=\"http://www.streetinsider.com/\" target=\"_blank\">notes</a> that Finish Line gave up some sales growth due to recent traffic-inducing promotional activity and is wary of the company's future track.</li> <li>\"Management spoke of a realignment of the apparel business closer to the footwear segment, but we think that process will take time and is a subject to an execution risk. We also question whether the elevated discounts are a way to address some other issues in the FINL\u2019s footwear business,\" he notes.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231902-finish-line-crushed-posting-slow-sales-growth\" target=\"_blank\">Finish Line crushed after posting slow sales growth</a> (Dec. 21)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232230\" data-linked=\"Finish Line sliced and diced by analysts after earnings\" data-tweet=\"$FINL - Finish Line sliced and diced by analysts after earnings https://seekingalpha.com/news/3232230-finish-line-sliced-and-diced-analysts-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3232230-finish-line-sliced-and-diced-analysts-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232228\" data-ts=\"1482420514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVUS\" target=\"_blank\">NVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232228-tokai-pharma-up-big-on-share-purchase-deal-otic-pharma-shares-ahead-57\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tokai Pharma up big on share purchase deal with Otic Pharma; shares ahead 57%</a></h4><ul>\n<li>Nano cap Tokai Pharmaceuticals (TKAI <font color=\"green\">+57.4%</font>) jumps on a 12x surge in volume in response its announcement of a share purchase agreement with privately held Otic Pharma Ltd. whereby Otic will become majority owner.</li>\n<li>The combined company will focus on developing and commercializing products for ear, nose and throat disorders. Otic's lead program is OP-02, a combo drug to treat otitis media (ear infection) and Eustachian tube dysfunction.</li>\n<li>Under the terms of the agreement, Otic will receive 32,172,209 newly issued Tokai common shares. Tokai will assume outstanding Otic options and convertible securities. After the exchange, Otic shareholder will own ~60% of the combined enterprise and Tokai shareholders will own ~40%.</li>\n<li>The deal should close next quarter.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232228\" data-linked=\"Tokai Pharma up big on share purchase deal with Otic Pharma; shares ahead 57%\" data-tweet=\"$NVUS - Tokai Pharma up big on share purchase deal with Otic Pharma; shares ahead 57% https://seekingalpha.com/news/3232228-tokai-pharma-up-big-on-share-purchase-deal-otic-pharma-shares-ahead-57?source=tweet\" data-url=\"https://seekingalpha.com/news/3232228-tokai-pharma-up-big-on-share-purchase-deal-otic-pharma-shares-ahead-57\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232226\" data-ts=\"1482419939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TALO\" target=\"_blank\">TALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232226-stone-energyminus-9-equity-committee-request-resolved\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stone Energy -9% as equity committee request resolved</a></h4><ul><li>Stone Energy (SGY <font color=\"red\">-9.2%</font>) shareholders are to get 5% of the common shares of the reorganized company (up from 4% previously), and warrants for another 15% (up from 10% previously).</li></ul><div class=\"tiny-share-widget\" data-id=\"3232226\" data-linked=\"Stone Energy -9% as equity committee request resolved\" data-tweet=\"$TALO - Stone Energy -9% as equity committee request resolved https://seekingalpha.com/news/3232226-stone-energyminus-9-equity-committee-request-resolved?source=tweet\" data-url=\"https://seekingalpha.com/news/3232226-stone-energyminus-9-equity-committee-request-resolved\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232225\" data-ts=\"1482419812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232225-mattel-and-hasbro-lower-after-reports-of-sluggish-toy-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel and Hasbro lower after reports of sluggish toy demand</a></h4><ul> <li>Mattel (<a href=\"https://seekingalpha.com/symbol/MAT\" title=\"Mattel, Inc.\">MAT</a> <font color=\"red\">-2.6%</font>) and Hasbro (<a href=\"https://seekingalpha.com/symbol/HAS\" title=\"Hasbro, Inc.\">HAS</a> <font color=\"red\">-2.3%</font>) are both lower in reaction to yesterday's <a href=\"https://www.npd.com/wps/portal/npd/us/news/press-releases/2016/during-the-sixth-week-lull-of-holiday-16-in-store-and-online-sales-shortfall-deepened-new-dynamics-and-the-final-shopping-push-will-be-critical/\" target=\"_blank\">report</a> from NPD Group that toy sales were down 9% during the sixth week of the holiday season.</li>  <li>In related sector news, Toys 'R' Us CEO Dave Brandon confirmed that the toy industry saw soft soft sales trends for the last three months.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232225\" data-linked=\"Mattel and Hasbro lower after reports of sluggish toy demand\" data-tweet=\"$MAT $MAT $HAS - Mattel and Hasbro lower after reports of sluggish toy demand https://seekingalpha.com/news/3232225-mattel-and-hasbro-lower-after-reports-of-sluggish-toy-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3232225-mattel-and-hasbro-lower-after-reports-of-sluggish-toy-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232223\" data-ts=\"1482419748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232223-teva-pays-519m-to-settle-u-s-fcpa-investigation-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva pays $519M to settle U.S. FCPA investigation; shares up 2%</a></h4><ul>\n<li>Teva Pharmaceutical Industries (<a href=\"https://seekingalpha.com/symbol/TEVA\" title=\"Teva Pharmaceutical Industries Limited\">TEVA</a> <font color=\"green\">+1.7%</font>) reaches a settlement with the U.S. Department of Justice and SEC over alleged violations of the Foreign Corrupt Practices Act (FCPA) related to past conduct in Ukraine, Russia and Mexico.</li>\n<li>The resolution includes a guilty plea by its Russian subsidiary, a deferred prosecution agreement, the implementation of a temporary independent compliance monitor and the payment of $519M.</li>\n<li>The inquiry, which began in 2012, involved improper payments by then-employees, all since dismissed from the company. None of the issues involved Teva's U.S. operations.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232223\" data-linked=\"Teva pays $519M to settle U.S. FCPA investigation; shares up 2%\" data-tweet=\"$TEVA - Teva pays $519M to settle U.S. FCPA investigation; shares up 2% https://seekingalpha.com/news/3232223-teva-pays-519m-to-settle-u-s-fcpa-investigation-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3232223-teva-pays-519m-to-settle-u-s-fcpa-investigation-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232221\" data-ts=\"1482419523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVI\" target=\"_blank\">CVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232221-cvr-energy-cvr-refining-up-8-icahn-heads-to-d-c\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CVR Energy, CVR Refining each up 8% as Icahn heads to D.C.</a></h4><ul><li>Donald Trump late yesterday<a href=\"https://seekingalpha.com/news/3232076-icahn-named-adviser-trump-regulatory-overhaul-wsj\" target=\"_blank\"> tapped Carl Icahn</a> to be his special advisor on regulation. He will serve, however, in an \"individual capacity,\" meaning he won't have to cash out of any of his businesses.</li><li>CVR Energy (<a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+8%</font>) (in which Icahn holds a controlling stake) and CVR Refining (<a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='green'>+7.7%</font>).</li><li>Related: PBF Energy (<a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='green'>+3.8%</font>), HollyFrontier (<a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+2.2%</font>), Delek (<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='green'>+0.9%</font>), Valero (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='green'>+1%</font>), Western Refining (<a href='https://seekingalpha.com/symbol/WNR' title='Western Refining, Inc.'>WNR</a> <font color='green'>+1%</font>), Tesoro (TSO <font color='green'>+0.7%</font>), Marathon (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+2.2%</font>), Phillips 66 (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='green'>+0.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3232221\" data-linked=\"CVR Energy, CVR Refining each up 8% as Icahn heads to D.C.\" data-tweet=\"$CVI $CVI $CVRR - CVR Energy, CVR Refining each up 8% as Icahn heads to D.C. https://seekingalpha.com/news/3232221-cvr-energy-cvr-refining-up-8-icahn-heads-to-d-c?source=tweet\" data-url=\"https://seekingalpha.com/news/3232221-cvr-energy-cvr-refining-up-8-icahn-heads-to-d-c\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232215\" data-ts=\"1482418976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUN\" target=\"_blank\">SUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232215-sunocosplus-6_5-bounce-continues-fbr-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunoco&#39;s +6.5%; bounce continues as FBR upgrades</a></h4><ul>\n<li>It's two upgrades in two days for Sunoco (NYSE:<a href=\"https://seekingalpha.com/symbol/SUN\" title=\"Sunoco LP\">SUN</a>) as FBR's Robert Balsamo boosts to Outperform. His $32 price target suggests more than <font color=\"green\">35% upside</font> from yesterday's close.</li>\n<li>Shares are <font color=\"green\">higher by 6.5%</font> today to $25.08.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232011-sunoco-upgraded-credit-suisse-says-distribution-cut-unlikely\" target=\"_blank\">Sunoco upgraded at Credit Suisse, which says distribution cut unlikely</a> (Dec. 21)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232215\" data-linked=\"Sunoco&#39;s +6.5%; bounce continues as FBR upgrades\" data-tweet=\"$SUN - Sunoco&#39;s +6.5%; bounce continues as FBR upgrades https://seekingalpha.com/news/3232215-sunocosplus-6_5-bounce-continues-fbr-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3232215-sunocosplus-6_5-bounce-continues-fbr-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232209\" data-ts=\"1482418172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTK\" target=\"_blank\">FTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232209-mha-says-original-flotek-conclusion-still-valid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MHA says original Flotek conclusion still valid</a></h4><ul>\n<li>Flotek (<a href=\"https://seekingalpha.com/symbol/FTK\" title=\"Flotek Industries, Inc.\">FTK</a> <font color=\"green\">+5.1%</font>) is trading higher after disclosing that it received a letter from MHA Petroleum Consultants responding to criticisms by FourWorld Capital Management and others of prior reports prepared by MHA for the company regarding the efficacy of the company's CnF chemical products.</li>\n<li><a href=\"https://seekingalpha.com/filing/3332885\" target=\"_blank\">SEC Form 8-K </a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232209\" data-linked=\"MHA says original Flotek conclusion still valid\" data-tweet=\"$FTK - MHA says original Flotek conclusion still valid https://seekingalpha.com/news/3232209-mha-says-original-flotek-conclusion-still-valid?source=tweet\" data-url=\"https://seekingalpha.com/news/3232209-mha-says-original-flotek-conclusion-still-valid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232208\" data-ts=\"1482418013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/W\" target=\"_blank\">W</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232208-data-miner-m-science-positive-on-wayfair\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data miner M Science positive on Wayfair</a></h4><ul> <li>Shares of Wayfair (<a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a> <font color='green'>+2.5%</font>) are on watch on <a href=\"https://twitter.com/thenotablecalls/status/811942397739417600\" target=\"_blank\">word</a>&nbsp;from <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a> that <a href=\"http://www.mscience.com/\" target=\"_blank\">M Science</a> is raising Q4 estimates above Street expectations.</li> <li>M Science relies on data mining for many of its forecasts, instead of \"anecdotal\" guesswork.</li> <li>In the past, the firm has been ahead of the curve with its estimates, although it missed with Netflix in Q3.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232208\" data-linked=\"Data miner M Science positive on Wayfair\" data-tweet=\"$W - Data miner M Science positive on Wayfair https://seekingalpha.com/news/3232208-data-miner-m-science-positive-on-wayfair?source=tweet\" data-url=\"https://seekingalpha.com/news/3232208-data-miner-m-science-positive-on-wayfair\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232205\" data-ts=\"1482417308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232205-globalstarplus-20_4-on-report-tlps-needed-fcc-votes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar +20.4% on report TLPS has needed FCC votes</a></h4><ul>   <li>Globalstar (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a>) has opened <font color=\"green\">up 20.4%</font>, gapping to $1.77 (highest since early June) on reports that the company's recently revised proposal for its Terrestrial Low-Power Service is getting the needed three votes at the FCC.</li>    <li>Chairman Tom Wheeler is said to be joining the panel's Republicans, Ajit Pai and Mike O'Rielly, to OK the proposal.</li>    <li>The stock had jumped last week just on news that the <a href=\"https://seekingalpha.com/news/3231388-globalstar-plus-29-percent-fcc-circulates-revised-proposal\" target=\"_blank\">FCC was circulating the revision</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232205\" data-linked=\"Globalstar +20.4% on report TLPS has needed FCC votes\" data-tweet=\"$GSAT - Globalstar +20.4% on report TLPS has needed FCC votes https://seekingalpha.com/news/3232205-globalstarplus-20_4-on-report-tlps-needed-fcc-votes?source=tweet\" data-url=\"https://seekingalpha.com/news/3232205-globalstarplus-20_4-on-report-tlps-needed-fcc-votes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232200\" data-ts=\"1482416481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRED\" target=\"_blank\">FRED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232200-freds-spins-lower-after-soft-rite-aid-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fred&#39;s spins lower after soft Rite Aid results</a></h4><ul> <li>Shares of Fred's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FRED\" title=\"Fred's, Inc.\">FRED</a>) are down sharply in early trading after a disappointing read from Rite Aid on sales growth.</li> <li>Fred's has plenty of skin in the game after its huge deal to acquite 865 Rite Aid stores.</li> <li>FRED <font color=\"red\">-8.11%</font> premarket to $18.70, although the damage isn't so bad considering the drugstore stock is still up 87% for the week.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232165-rite-aid-beats-profit-estimates-despite-pharmacy-pressure\" target=\"_blank\">Rite Aid beats profit estimates despite pharmacy pressure</a> (Dec. 22)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232200\" data-linked=\"Fred&#39;s spins lower after soft Rite Aid results\" data-tweet=\"$FRED - Fred&#39;s spins lower after soft Rite Aid results https://seekingalpha.com/news/3232200-freds-spins-lower-after-soft-rite-aid-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3232200-freds-spins-lower-after-soft-rite-aid-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232199\" data-ts=\"1482416372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232199-xoma-monetizes-two-royalty-streams-for-22m-shares-up-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA monetizes two royalty streams for $22M; shares up 11% premarket</a></h4><ul>\n<li>(NASDAQ:<a href=\"https://seekingalpha.com/symbol/XOMA\" title=\"XOMA Corporation\">XOMA</a>) is up <font color=\"green\">11%</font> premarket on average volume in response to its announcement that it has sold its royalty streams from two license agreements related to its patented bacterial cell expression technology to HealthCare Royalty Partners for $22M ($18M upfront + $4M in milestones). The first pertains to TRUMENBA, a meningococcal group B vaccine marketed by Pfizer, and the second to Dyax.</li>\n<li>The company is also narrowing its focus on clinical development , led by XOMA 358, that will necessitate the elimination of 57 employees. CEO John Varian will retire and be succeeded by Jim Neal.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232199\" data-linked=\"XOMA monetizes two royalty streams for $22M; shares up 11% premarket\" data-tweet=\"$XOMA - XOMA monetizes two royalty streams for $22M; shares up 11% premarket https://seekingalpha.com/news/3232199-xoma-monetizes-two-royalty-streams-for-22m-shares-up-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3232199-xoma-monetizes-two-royalty-streams-for-22m-shares-up-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232198\" data-ts=\"1482416068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232198-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li>\n<b>Gainers:</b> TKAI <font color=\"green\">+39%</font>. <a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/CETX\" title=\"Cemtrex, Inc.\">CETX</a> <font color=\"green\">+19%</font>. <a href=\"https://seekingalpha.com/symbol/EYES\" title=\"Second Sight Medical Products\">EYES</a> <font color=\"green\">+16%</font>. <a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/WTW\" title=\"Weight Watchers International, Inc.\">WTW</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/CVRR\" title=\"CVR Refining, LP\">CVRR</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/VCEL\" title=\"Vericel Corporation\">VCEL</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/RENN\" title=\"Renren Inc.\">RENN</a> <font color=\"green\">+9%</font>. <a href=\"https://seekingalpha.com/symbol/FTK\" title=\"Flotek Industries, Inc.\">FTK</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/CATB\" title=\"Catabasis Pharmaceuticals\">CATB</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/SINO\" title=\"Sino-Global Shipping America, Ltd.\">SINO</a> <font color=\"green\">+5%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/OVAS-OLD\" title=\"OvaScience, Inc.\">OVAS-OLD</a> <font color=\"red\">-29%</font>. <a href=\"https://seekingalpha.com/symbol/AUPH\" title=\"Aurinia Pharmaceuticals Inc.\">AUPH</a> <font color=\"red\">-22%</font>. <a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a> <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/INAP\" title=\"Internap Network Services Corporation\">INAP</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/FRED\" title=\"Fred's, Inc.\">FRED</a> <font color=\"red\">-8%</font>. SGY <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/CALA\" title=\"Calithera Biosciences\">CALA</a> <font color=\"red\">-5%</font>. <a href=\"https://seekingalpha.com/symbol/GST\" title=\"Gastar Exploration Inc.\">GST</a> <font color=\"red\">-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232198\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$NVUS $GSAT $CETX - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3232198-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3232198-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232195\" data-ts=\"1482415528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232195-needham-company-issues-two-level-upgrade-to-buy-on-micron-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham &amp; Company issues two-level upgrade to Buy on Micron Technology</a></h4><ul>\n<li>Following Micron Technology's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a>) <a href=\"https://seekingalpha.com/news/3232079-micron-technology-plus-7_4-percent-q1-estimates-outlook-robust\" target=\"_blank\">strong Q1 reporting and Q2 forecasting</a>, <a href=\"http://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Upgrades+Micron+Technology+%28MU%29+Two-Notches+to+Buy%2C+%2433+PT/12366128.html\" target=\"_blank\">analyst Rajvindra Gill</a> elevates from Underperform, citing regained customer positioning in 20nm, successful migration to 3D NAND (2nd-generation 64-layer), improved DRAM pricing climate, extensive range of product targets (cloud computing, data centers, networking, graphics, automotive/ADAS), ongoing cost conversions in DRAM and 3D NAND, and gross margins he believes may near 36% in late 2017, leading to EPS of $3.30.</li>\n<li>Sets target on shares at $33 (pre-market price $23.07).</li>\n<li>\n<strong>Other target increases</strong> \u2013 J.P. Morgan to $28, Mizuho Securities to $27, Susquehanna to $25, Baird to $25, Deutsche Bank to $26, Wells Fargo to $25-$30 valuation range, Brean Capital to $28</li>\n<li><a href=\"https://seekingalpha.com/article/4032098-micron-technologys-mu-ceo-mark-durcan-q1-2017-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li>\n<li><a href=\"https://seekingalpha.com/article/4032065-micron-technology-inc-2017-q1-results-earnings-call-slides\" target=\"_blank\">Presentation slides</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232195\" data-linked=\"Needham &amp; Company issues two-level upgrade to Buy on Micron Technology\" data-tweet=\"$MU - Needham &amp; Company issues two-level upgrade to Buy on Micron Technology https://seekingalpha.com/news/3232195-needham-company-issues-two-level-upgrade-to-buy-on-micron-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3232195-needham-company-issues-two-level-upgrade-to-buy-on-micron-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232194\" data-ts=\"1482415488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OVAS-OLD\" target=\"_blank\">OVAS-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232194-ovascience-to-restructure-and-slow-commercial-expansion-of-augment-shares-down-31-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OvaScience to restructure and slow commercial expansion of AUGMENT; shares down 31% premarket</a></h4><ul>\n<li>OvaScience (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OVAS-OLD\" title=\"OvaScience, Inc.\">OVAS-OLD</a>) slumps <font color=\"red\">31%</font> premarket on increased volume in response to its announcement that it will slow the commercial expansion of its <a href=\"http://www.augmenttreatment.com/#why-augment\" target=\"_blank\">AUGMENT </a>egg health improvement service as well as reevaluate its ongoing and planned clinical studies related to the service. The move is part of its restructuring in order to extend its cash runway into Q1 2019 while it focuses on developing OvaPrime and OvaTure.</li>\n<li>The company intends to cut staff by ~30%, including the departure of President &amp; CEO Harald Stock, Ph.D. and COO Paul Chapman. Executive chair and co-founder Michelle Dipp, M.D., Ph.D,, will run the company until a new CEO is hired.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232194\" data-linked=\"OvaScience to restructure and slow commercial expansion of AUGMENT; shares down 31% premarket\" data-tweet=\"$OVAS-OLD - OvaScience to restructure and slow commercial expansion of AUGMENT; shares down 31% premarket https://seekingalpha.com/news/3232194-ovascience-to-restructure-and-slow-commercial-expansion-of-augment-shares-down-31-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3232194-ovascience-to-restructure-and-slow-commercial-expansion-of-augment-shares-down-31-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232174\" data-ts=\"1482412969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232174-store-weakness-clips-bed-bath-beyond\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Store weakness clips Bed Bath &amp; Beyond</a></h4><ul> <li>Comparable sales fell 1.4% at Bed Bath &amp; Beyond (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BBBY\" title=\"Bed Bath &amp; Beyond Inc.\">BBBY</a>) in Q3 to miss the analyst average of +0.5%.</li> <li>A +20% gain in comparable sales from digital channels helped to diminish the impact from a low single-digit drop in comparable sales at stores.</li> <li>Looking ahead, the company sees Q3 sales of $2.96B vs. $3.01B consensus and EPS of $0.85.</li> <li>Raymond James lowers BBBY to Market Perform from Strong Buy after losing faith it can realize tech investments benefits quickly. Nomura and Goldman Sachs stick with Neutral ratings on BBBY.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232074-bed-bath-and-beyond-misses-0_13-misses-revenue\" target=\"_blank\">Bed Bath &amp; Beyond misses by $0.13, misses on revenue</a> (Dec. 21)</li> <li>Shares of Bed Bath &amp; Beyond are <font color=\"red\">down 3.86%</font> premarket to $43.80.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232174\" data-linked=\"Store weakness clips Bed Bath &amp; Beyond\" data-tweet=\"$BBBY - Store weakness clips Bed Bath &amp; Beyond https://seekingalpha.com/news/3232174-store-weakness-clips-bed-bath-beyond?source=tweet\" data-url=\"https://seekingalpha.com/news/3232174-store-weakness-clips-bed-bath-beyond\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232154\" data-ts=\"1482409784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUPH\" target=\"_blank\">AUPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232154-aurinia-announces-25m-underwriting-offering-shares-off-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurinia announces $25M underwriting offering, shares off 19% premarket</a></h4><ul> <li>Aurinia Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AUPH\" title=\"Aurinia Pharmaceuticals Inc.\">AUPH</a>) announces that it has entered into an       underwriting agreement with H.C. Wainwright &amp; Co., LLC and Cormark Securities under which the Underwriters have       agreed to purchase 11M units from the Company at       the price of US$2.25 per unit for aggregate gross       proceeds of ~US$25M.</li>\n<li>Each Unit consists of one common share of       the Company and one-half of a warrant to buy one share, with       an exercise price of $3.00 per whole warrant. Underwriters can purchase up to an additional       1.7M units at the issue price for additional proceeds of up to       ~US$3.75M. In the event the Over-Allotment Option is       exercised in full, the gross proceeds will be       ~US$28.8 million.</li>          <li>Offering is expected to close on or about December       28.</li>\n<li>Shares are down <font color=\"red\">19%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3232154\" data-linked=\"Aurinia announces $25M underwriting offering, shares off 19% premarket\" data-tweet=\"$AUPH - Aurinia announces $25M underwriting offering, shares off 19% premarket https://seekingalpha.com/news/3232154-aurinia-announces-25m-underwriting-offering-shares-off-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3232154-aurinia-announces-25m-underwriting-offering-shares-off-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":52,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}